Despite persistent domestic policy pressures, China’s dynamic healthcare sector is successfully leveraging innovation, particularly in artificial intelligence, and strategic global expansion to drive impressive financial performance. A recent analysis by UOB Kay Hian highlights a nuanced landscape where most leading healthcare enterprises reported satisfactory financial outcomes for 2025, demonstrating robust revenue and earnings growth. This positive trajectory, in our view, is predominantly concentrated within high-growth segments such as biopharmaceuticals, contract research and manufacturing services (CRDMOs), and advanced internet healthcare platforms.
Biopharma’s Global Ambitions and Cross-Border Collaboration
Drug manufacturers within China are increasingly pivoting towards more lucrative licensing agreements and fostering international partnerships. This strategic shift allows companies to effectively monetize their research pipelines on a global scale. As the UOB Kay Hian report aptly observes, “Licence income becomes a new source of growth,” indicating a clear pathway for these firms to generate substantial revenue beyond their domestic market.
Biopharma companies are actively pursuing an increased number of cross-border licensing deals, while CRDMOs are diligently strengthening their relationships with multinational pharmaceutical clients. This dual approach not only diversifies revenue streams but also enhances China’s standing as a significant player in the global healthcare ecosystem, potentially attracting a greater influx of international patients seeking innovative treatments.
CRDMOs: A Global Healthcare Powerhouse
China’s CRDMO sector continues to stand out as a primary beneficiary of surging global demand. Leading firms like WuXi AppTec and WuXi Bio exemplified this trend, both reporting impressive revenue and earnings growth in 2025. This success, in our expert opinion, is directly attributable to the escalating demand from international biopharmaceutical companies seeking efficient and high-quality research and manufacturing services. Their capabilities are crucial for maintaining the quality of care in pharmaceutical development worldwide.
The AI Revolution in Digital Health and Medical Devices
Artificial intelligence (AI) is rapidly emerging as a decisive competitive advantage across the Chinese healthcare landscape. Internet healthcare platforms are harnessing AI to significantly enhance operational efficiency, improve the delivery of services, and expand profit margins. For instance, Ali Health anticipates revenue growth ranging from 10% to 15% and a net profit expansion of 20% to 30%. Similarly, Ping An Good Doctor is projected to achieve a substantial profit growth of approximately 40%. These figures underscore the transformative potential of AI in digital health, which could also bolster wellness tourism and international patient care by offering accessible, high-tech solutions.
Furthermore, corporate health management services are gaining considerable traction, with expectations that they could contribute over half of total revenue for some platforms within the next three to five years. AI’s impact extends into the medical device sector, particularly in cutting-edge categories such as surgical robotics. Innovators like Edge Medical and MicroPort MedBot have reported remarkable revenue growth of 185% and 114% respectively, signaling a significant leap in advanced medical technology that could position China as a leading healthcare destination for specialized patient travel.
Persistent Domestic Pressures on Traditional Segments
However, it is crucial to acknowledge that not all segments of the Chinese healthcare industry are enjoying equal benefits from these advancements. Traditional healthcare businesses continue to face considerable pressure stemming from ongoing policy reforms. Medical device companies, excluding the high-growth robotics segment, have been particularly impacted by rigorous anti-corruption campaigns and volume-based procurement (VBP) programs. These initiatives have inevitably squeezed pricing and decelerated overall growth within this sector.
Similar challenges are confronting the drug distribution segment. Sinopharm, for example, reported flat revenue and earnings, with only modest growth anticipated for 2026. This stagnation is largely attributed to the sustained influence of centralized procurement policies and budget constraints within the public healthcare system, which continue to exert downward pressure on profit margins.
The traditional Chinese medicine (TCM) segment has experienced a particularly severe downturn. China TCM reported a 10.7% decline in revenue and a significant 47.5% drop in profit, while Shineway also posted double-digit revenue declines. This vulnerability highlights the challenges faced by certain traditional sectors in adapting to modern policy frameworks and market dynamics, illustrating a clear divergence in performance across the broader healthcare spectrum.
Bottom Line
Despite the significant domestic policy headwinds, China’s healthcare sector demonstrates remarkable resilience and strategic foresight. The robust performance of innovative segments like biopharmaceuticals, CRDMOs, and AI-driven internet healthcare platforms, coupled with their aggressive global expansion, is effectively offsetting the pressures on more traditional areas. From our perspective, this strategic pivot underscores a clear intent to elevate China’s position as a formidable global healthcare player and a significant healthcare destination for international patients. While challenges persist, the overall outlook remains positive, with analysts maintaining an ‘overweight’ stance on the sector, reflecting confidence in its long-term growth trajectory and its increasing role in cross-border healthcare.
The news signal for this article was referred from: https://healthcareasiamagazine.com/healthcare/news/china-healthcare-firms-offset-policy-pressure-global-growth